Eli Lilly - 15 Year Stock Price History | LLY
Historical daily share price chart and data for Eli Lilly since 2011 adjusted for splits and dividends. The latest closing stock price for Eli Lilly as of September 04, 2026 is 1149.36.
- The all-time high Eli Lilly stock closing price was 1280.34 on August 19, 2026.
- The Eli Lilly 52-week high stock price is 1292.65, which is 12.5% above the current share price.
- The Eli Lilly 52-week low stock price is 712.05, which is 38% below the current share price.
- The average Eli Lilly stock price for the last 52 weeks is 1016.09.
| Eli Lilly Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 1062.8766 | 1075.1700 | 1280.3400 | 848.5310 | 1149.3600 | 7.47% |
| 2025 | 820.8784 | 768.5960 | 1104.6000 | 620.3660 | 1069.5100 | 40.25% |
| 2024 | 798.5770 | 581.1960 | 946.7630 | 581.1960 | 762.6000 | 33.30% |
| 2023 | 454.2971 | 354.7090 | 606.5050 | 302.8570 | 572.0890 | 60.91% |
| 2022 | 297.1800 | 260.5480 | 364.2040 | 225.9720 | 355.5350 | 34.24% |
| 2021 | 214.0467 | 156.3240 | 267.5570 | 155.2100 | 264.8530 | 66.07% |
| 2020 | 139.2349 | 122.4330 | 163.0590 | 110.8170 | 159.4790 | 31.03% |
| 2019 | 106.7641 | 104.0360 | 122.6360 | 97.7789 | 121.7100 | 16.14% |
| 2018 | 83.9344 | 74.8065 | 107.4410 | 65.5573 | 104.7960 | 40.45% |
| 2017 | 71.7380 | 64.2235 | 77.6422 | 64.2063 | 74.6121 | 17.83% |
| 2016 | 64.9356 | 69.4791 | 71.0415 | 56.7939 | 63.3195 | -10.37% |
| 2015 | 65.2918 | 57.2125 | 74.9649 | 56.2641 | 70.6445 | 25.39% |
| 2014 | 49.6271 | 40.1016 | 59.4746 | 40.1016 | 56.3387 | 39.75% |
| 2013 | 40.8819 | 37.7217 | 44.8502 | 37.2982 | 40.3150 | 7.29% |
| 2012 | 32.5175 | 30.4148 | 40.5747 | 28.3599 | 37.5770 | 24.26% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1081.958B | $65.179B |
| Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Johnson & Johnson (JNJ) | United States | $663.276B | 25.34 |
| AbbVie (ABBV) | United States | $453.112B | 23.59 |
| Merck (MRK) | United States | $370.890B | 46.83 |
| Roche Holding AG (RHHBY) | Switzerland | $350.157B | 0.00 |
| Novartis AG (NVS) | Switzerland | $305.285B | 18.43 |
| Novo Nordisk (NVO) | Denmark | $208.069B | 11.59 |
| Pfizer (PFE) | United States | $162.156B | 9.33 |
| Sanofi (SNY) | France | $107.257B | 9.03 |
| Bayer (BAYRY) | Germany | $55.767B | 9.92 |
| Innoviva (INVA) | United States | $1.541B | 5.27 |